Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1996 Jan;64(1):23–27. doi: 10.1128/iai.64.1.23-27.1996

Further characterization of delta aroA delta virG Shigella flexneri 2a strain CVD 1203 as a mucosal Shigella vaccine and as a live-vector vaccine for delivering antigens of enterotoxigenic Escherichia coli.

F R Noriega 1, G Losonsky 1, J Y Wang 1, S B Formal 1, M M Levine 1
PMCID: PMC173722  PMID: 8557344

Abstract

The use of attenuated delta aroA delta virG Shigella flexneri 2a strain CVD 1203 as a live vector for enterotoxigenic Escherichia coli (ETEC) antigens is reported. CVD 1203 alone or expressing colonization factor antigen fimbriae and CS3 fibrillae of ETEC was given to guinea pigs and mice, orogastrically (o.g.) or intranasally (i.n.). CVD 1203 given i.n. elicited high titers of antilipopolysaccharide (anti-LPS) immunoglobulin A (IgA) and was protective in guinea pigs against a homologous conjunctival challenge. Whereas a strong IgA response against colonization factor antigen CS3, and Shigella LPS was detected in tears and serum of guinea pigs after o.g. or i.n. immunization, the i.n. route elicited significantly higher antibody titers. A strong serum IgG response was also observed against the ETEC antigens, although no serum anti-LPS IgG response was detected. The immune response in mice followed a pattern similar to that in guinea pigs, and the difference between the responses after o.g. and i.n. administration was even more remarkable.

Full Text

The Full Text of this article is available as a PDF (270.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Couch R. B. Advances in influenza virus vaccine research. Ann N Y Acad Sci. 1993 Jun 23;685:803–812. doi: 10.1111/j.1749-6632.1993.tb35946.x. [DOI] [PubMed] [Google Scholar]
  2. DuPont H. L., Hornick R. B., Dawkins A. T., Snyder M. J., Formal S. B. The response of man to virulent Shigella flexneri 2a. J Infect Dis. 1969 Mar;119(3):296–299. doi: 10.1093/infdis/119.3.296. [DOI] [PubMed] [Google Scholar]
  3. FORMAL S. B., DAMMIN G. J., LABREC E. H., SCHNEIDER H. Experimental Shigella infections: characteristics of a fatal infection produced in guinea pigs. J Bacteriol. 1958 May;75(5):604–610. doi: 10.1128/jb.75.5.604-610.1958. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Girón J. A., Xu J. G., González C. R., Hone D., Kaper J. B., Levine M. M. Simultaneous expression of CFA/I and CS3 colonization factor antigens of enterotoxigenic Escherichia coli by delta aroC, delta aroD Salmonella typhi vaccine strain CVD 908. Vaccine. 1995 Jul;13(10):939–946. doi: 10.1016/0264-410x(95)00003-j. [DOI] [PubMed] [Google Scholar]
  5. Hall R. H., Maneval D. R., Jr, Collins J. H., Theibert J. L., Levine M. M. Purification and analysis of colonization factor antigen I, coli surface antigen 1, and coli surface antigen 3 fimbriae from enterotoxigenic Escherichia coli. J Bacteriol. 1989 Nov;171(11):6372–6374. doi: 10.1128/jb.171.11.6372-6374.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Kotloff K. L., Losonsky G. A., Nataro J. P., Wasserman S. S., Hale T. L., Taylor D. N., Newland J. W., Sadoff J. C., Formal S. B., Levine M. M. Evaluation of the safety, immunogenicity, and efficacy in healthy adults of four doses of live oral hybrid Escherichia coli-Shigella flexneri 2a vaccine strain EcSf2a-2. Vaccine. 1995 Apr;13(5):495–502. doi: 10.1016/0264-410x(94)00011-b. [DOI] [PubMed] [Google Scholar]
  7. Langermann S., Palaszynski S., Sadziene A., Stover C. K., Koenig S. Systemic and mucosal immunity induced by BCG vector expressing outer-surface protein A of Borrelia burgdorferi. Nature. 1994 Dec 8;372(6506):552–555. doi: 10.1038/372552a0. [DOI] [PubMed] [Google Scholar]
  8. Levine M. M., Bergquist E. J., Nalin D. R., Waterman D. H., Hornick R. B., Young C. R., Sotman S. Escherichia coli strains that cause diarrhoea but do not produce heat-labile or heat-stable enterotoxins and are non-invasive. Lancet. 1978 May 27;1(8074):1119–1122. doi: 10.1016/s0140-6736(78)90299-4. [DOI] [PubMed] [Google Scholar]
  9. Levine M. M. Escherichia coli that cause diarrhea: enterotoxigenic, enteropathogenic, enteroinvasive, enterohemorrhagic, and enteroadherent. J Infect Dis. 1987 Mar;155(3):377–389. doi: 10.1093/infdis/155.3.377. [DOI] [PubMed] [Google Scholar]
  10. Levine M. M., Nalin D. R., Hoover D. L., Bergquist E. J., Hornick R. B., Young C. R. Immunity to enterotoxigenic Escherichia coli. Infect Immun. 1979 Mar;23(3):729–736. doi: 10.1128/iai.23.3.729-736.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Mestecky J., McGhee J. R. Prospects for human mucosal vaccines. Adv Exp Med Biol. 1992;327:13–23. doi: 10.1007/978-1-4615-3410-5_3. [DOI] [PubMed] [Google Scholar]
  12. Natuk R. J., Davis A. R., Chanda P. K., Lubeck M. D., Chengalvala M., Murthy S. C., Wade M. S., Dheer S. K., Bhat B. M., Murthy K. K. Adenovirus vectored vaccines. Dev Biol Stand. 1994;82:71–77. [PubMed] [Google Scholar]
  13. Noriega F. R., Wang J. Y., Losonsky G., Maneval D. R., Hone D. M., Levine M. M. Construction and characterization of attenuated delta aroA delta virG Shigella flexneri 2a strain CVD 1203, a prototype live oral vaccine. Infect Immun. 1994 Nov;62(11):5168–5172. doi: 10.1128/iai.62.11.5168-5172.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Orr N., Robin G., Cohen D., Arnon R., Lowell G. H. Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models. Infect Immun. 1993 Jun;61(6):2390–2395. doi: 10.1128/iai.61.6.2390-2395.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. SERENY B. Experimental keratoconjunctivitis shigellosa. Acta Microbiol Acad Sci Hung. 1957;4(4):367–376. [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES